Prothrombotic markers in asymptomatic dyslipidemic subjects

Area of Science:

• Cardiovascular Medicine
• Clinical Biochemistry
• Thrombosis Research

Background:

• Dyslipidemia is a significant risk factor for cardiovascular disease.
• Prothrombotic markers play a crucial role in the development of atherosclerosis.
• Understanding these markers in different dyslipidemic phenotypes is essential for risk stratification.

Purpose of the Study:

• To evaluate plasma levels of von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA) in asymptomatic individuals with dyslipidemia.
• To investigate the association of these prothrombotic markers with lipid parameters, insulin resistance, and intima-media thickness (IMT).

Main Methods:

• Cross-sectional study of 234 asymptomatic subjects with dyslipidemia and their relatives.
• Classification into four dyslipidemic phenotypes (DLP) based on apolipoprotein B (apoB) and triglycerides (TG) levels.
• Measurement of plasma prothrombotic markers (vWF, PAI-1, t-PA) and assessment of atherosclerosis risk factors, including IMT.

Main Results:

• Significantly higher PAI-1 levels were observed in hypertriglyceridemic phenotypes (DLP2, DLP4) compared to the normolipidemic phenotype (DLP1).
• Elevated t-PA levels were found only in subjects with both high TG and high apoB (DLP4) compared to DLP1.
• vWF showed no significant differences between phenotypes but was independently associated with increased IMT, particularly in DLP4.

Conclusions:

• Hypertriglyceridemic dyslipidemia phenotypes are associated with increased PAI-1 levels.
• Simultaneous elevation of TG and apoB (DLP4) is linked to increased t-PA and IMT, indicating a higher risk for atherosclerosis.
• Prothrombotic marker profiles vary across dyslipidemic phenotypes, highlighting the need for tailored risk assessment.